title: Case report: BRCA in the Ashkenazi population: are current testing guidelines too exclusive?
abstract: The BRCA1/2 genes account for a significant portion of hereditary breast and ovarian cancers and they are especially prevalent in the Ashkenazi Jewish population. Women who have a mutation can prevent breast and ovarian cancer with surgical intervention. We describe an Ashkenazi Jewish patient who illustrates that current testing criteria are too restrictive, particularly for this population of patients. The patient's sister was diagnosed with breast cancer at age 33; however, she was not a mutation carrier. Based on practice guidelines, the patient was not recommended genetic testing. She subsequently underwent direct-to-consumer (DTC) testing and discovered that she was a mutation carrier. This case demonstrates the need for clinicians to be aware of the higher prevalence of BRCA mutations in the Ashkenazi population. It also exemplifies the need to involve medical professionals, including genetic counselors, in the dissemination of DNA test results.
authors.affiliation: Genetic Risk Assessment Program, Weill Cornell Breast Center, NewYork-Presbyterian Hospital, 425 East 61 Street, 10th Floor, New York, NY 10065, USA. ppressman1@gmail.com.
authors.forename: Katherine H
authors.initials: KH
authors.lastname: Saunders
authors.forename: Shivani
authors.initials: S
authors.lastname: Nazareth
authors.forename: Peter I
authors.initials: PI
authors.lastname: Pressman